initial public offerings (IPOs) trading on American exchanges

Friday, June 14, 2013

Portola Pharmaceuticals (PTLA) began trading on the NASDAQ on 22 May 2013

Portola Pharmaceuticals, which is developing a blood thinner and a novel reversal agent for acutely ill patients, raised $122 million in an upsized IPO by offering 8.4 million shares at $14.50, the midpoint of the $13 to $16 range. Portola commands a market cap of $491 million. The company originally set terms for a deal that would have raised $100 million at the midpoint and valued the company at a market cap of $469 million.

Portola Pharmaceuticals Inc. - South San Francisco, Calif., 6.9 million shares, priced $13 to $16, managed by Morgan Stanley and Credit Suisse. Proposed Nasdaq symbol PTLA. Business: Developing a blood thinner and a novel reversal agent for acutely ill patients.


Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options. The Company’s two lead programs address unmet medical needs in the area of thrombosis, or blood clots. The Company’s lead compound Betrixaban is an oral once-daily inhibitor of Factor Xa in Phase III development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism (VTE), in acute medically ill patients. The Company’s third product candidate, PRT2070, is an orally available kinase inhibitor being developed for hematologic, or blood, cancers and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase (Syk), and janus kinases (JAK), enzymes that regulate signaling pathways.

Portola Pharmaceuticals is led by CEO William Lis


270 E. Grand Avenue
United States
+1-650-2467000 (Phone)
+1-650-2467376 (Fax)


Key stats and ratios

Q2 (Jun '13)2012
Net profit margin-830.37%15.78%
Operating margin-843.52%15.07%
EBITD margin-17.00%
Return on average assets-45.67%6.70%
Return on average equity-3013.20%-

No comments:

Post a Comment